Arizona State Retirement System Decreases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Arizona State Retirement System trimmed its stake in Regeneron by 5.7% in Q4, selling 1,766 shares and now holding 29,232 shares valued at about $22.56 million.
• FDA approval for Otarmeni was announced and Regeneron said it will provide the gene therapy free to eligible U.S. patients; the company also reportedly secured three years of tariff relief, though a drug‑pricing "most‑favored‑nation" deal could pressure margins.
• Financials and outlook: Regeneron beat Q4 estimates with $11.44 EPS and $3.88 billion revenue, raised its quarterly dividend to $0.94, and holds a MarketBeat consensus of "Moderate Buy" with a $825.35 price target.

Arizona State Retirement System decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,232 shares of the biopharmaceutical company's stock after selling 1,766 shares during the quarter. Arizona State Retirement System's holdings in Regeneron Pharmaceuticals were worth $22,563,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. WPG Advisers LLC boosted its stake in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 25 shares in the last quarter. Atwood & Palmer Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 0.9% during the 4th quarter. Atwood & Palmer Inc. now owns 41,817 shares of the biopharmaceutical company's stock worth $32,277,000 after acquiring an additional 386 shares in the last quarter. Chicago Partners Investment Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 42.3% during the 4th quarter. Chicago Partners Investment Group LLC now owns 1,345 shares of the biopharmaceutical company's stock worth $1,014,000 after acquiring an additional 400 shares in the last quarter. Quent Long Short Global Small Cap Fund LP purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $369,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $296,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $751.57 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The firm has a 50-day moving average of $762.84 and a two-hundred day moving average of $731.09. The stock has a market cap of $79.46 billion, a P/E ratio of 18.08, a PEG ratio of 1.71 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts' consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm's revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the company posted $12.07 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.2 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares of the company's stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 3,774 shares of company stock valued at $2,942,738. Insiders own 7.02% of the company's stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni (lunsotogene parvec-cwha), the first gene therapy to restore hearing — pivotal CHORD data showed ~80% met the primary endpoint and 42% achieved normal hearing on longer follow‑up, marking a breakthrough product and validating Regeneron’s genetic‑medicine efforts. Read More.
• Positive Sentiment: Analyst support: TD Cowen raised its price target to $960 (buy) and Cantor Fitzgerald reaffirmed an overweight rating with an $800 target — institutional upgrades can support upside as investors re‑rate growth prospects. Read More.
• Positive Sentiment: Regeneron reportedly secured tariff relief from the U.S. government for three years as part of the deal, which mitigates some cost headwinds and is a near‑term financial benefit. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major access/PR move that increases uptake and public goodwill but has ambiguous near‑term revenue implications. Read More.
• Neutral Sentiment: Q1 preview / estimates: Research outlets (Zacks) are parsing Wall Street’s revenue and key‑metric estimates ahead of quarterly reporting — results will be important for near‑term stock direction. Read More.
• Neutral Sentiment: CEO Leonard Schleifer said Regeneron will provide Otarmeni for free in the U.S. but hasn’t decided on overseas pricing — international price strategy remains uncertain and will affect global revenue potential. Read More.
• Negative Sentiment: Drug‑pricing deal: Regeneron agreed to offer some prescriptions at “most‑favored‑nation” (MFN) prices and to lower U.S. drug costs under the administration deal — investors worry this could compress margins and reduce pricing power across the portfolio. Read More.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research analyst reports. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Barclays began coverage on Regeneron Pharmaceuticals in a research report on Friday, March 6th. They set an "overweight" rating and a $923.00 price objective for the company. Evercore lifted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a research report on Thursday, January 22nd. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $818.00 to $801.00 and set a "buy" rating for the company in a research report on Tuesday, March 31st. Finally, Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a "sector perform" rating in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $825.35.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.